A few 2025 trials pointed in the same direction: toward treatments built to modify disease biology and better ways to measure ...

Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.

The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.

The Kennedy College of Sciences, Department of Biological Sciences, invites you to attend a Ph.D. Proposal Defense in Applied Biology by Brandon Reder entitled "Morphological and physiological ...

Cytokinetics announced FDA approval of MYQORZO™ (aficamten) to treat adults with symptomatic obstructive hypertrophic ...

"HCM is a heart muscle disease associated with a significant symptom burden. This approval of a new drug, Myqorzo, represents ...

Slated for a Dec. 26 decision on Cytokinetics’ aficamten, the FDA has delivered an early Christmas present, awarding the South San Francisco biotech its first U.S. nod since its 1997 founding. | ...

From a global regulatory perspective, Cytokinetics is expanding its footprint rapidly. The drug received approval in China on ...

FDA approved CYTK's Myqorzo for oHCM. It reduces heart's pumping ability, has a warning for heart failure and expected to ...

Cytokinetics, Incorporated CYTK announced that the FDA approved its lead pipeline candidate, aficamten, for the treatment of ...

Stifel analysts said the label for cardiac myosin inhibitor Myqorzo is in line with their expectations and is differentiated compared with BMS’ Camzyos.

Cytokinetics has announced that the FDA has approved MYQORZO tablets in 5mg, 10mg, 15mg, and 20mg doses for adults with oHCM .